Eukaryotic translation initiation factor 3 subunit b is a novel oncogenic factor in prostate cancer

  • PDF / 1,463,677 Bytes
  • 8 Pages / 595.276 x 790.866 pts Page_size
  • 44 Downloads / 189 Views

DOWNLOAD

REPORT


Eukaryotic translation initiation factor 3 subunit b is a novel oncogenic factor in prostate cancer Ping Xiang1,2 · Youwen Sun2 · Zhiqing Fang1 · Keqiang Yan1 · Yidong Fan1 Received: 18 April 2020 / Accepted: 5 June 2020 © Springer Science+Business Media, LLC, part of Springer Nature 2020

Abstract Prostate cancer, the second most common cancer among male adults, affects millions globally. We sought to investigate the expression and contribution of Eukaryotic translation initiation factor 3 subunit b (EIF3B) in prostate cancer. Expression of EIF3B was analyzed in both human prostate patient tissues and prostate cancer cell lines. Small interfering RNA (siRNA) knockdown of EIF3B was introduced into prostate cancer cell line PC-3 and LNCaP, followed by examination of cell viability, proliferation and apoptosis using the MTT, cell counting and terminal deoxynucleotidyl transferase dUTP nick end labeling assays, respectively. An in vivo xenograft tumor mouse model was employed to address the role of EIF3B in tumorigenesis as well. Finally, a gene microarray analysis was performed to search for differentially expressed genes upon EIF3B knockdown. EIF3B was upregulated in prostate tumor tissues and prostate cancer cell lines. EIF3B knockdown inhibited viability and proliferation of prostate cancer cells, as well as promoted cell apoptosis. In the in vivo mouse model, inoculation of EIF3B knockdown PC-3 cells displayed inhibited growth of xenograft tumors. In addition, potential signaling pathways that might be involved in EIF3B action in prostate cancer were identified by the gene microarray. EIF3B is a novel oncogenic factor in prostate cancer both in vitro and in vivo, which could be employed as a novel therapeutic target in the treatment against prostate cancer.

Introduction Prostate gland, a male reproductive organ, produces semen as well as other types of fluids that protect the sperm cells. Abnormal growth of prostate cells results in prostate cancer. Among men, prostate cancer is the second most common cancer behind skin cancer. It is also the second leading cause of cancer-related death in the U.S. male population. However, in Asia, the prostate cancer incidence is much lower. Exogenous factors including dietary composition and other life style choices may partially account for the difference in the incidence rates among different ethnic groups (Bostwick et al. 2004; Pernar et al. 2018). Hence, accelerated westernization may lead to increased prostate cancer incidences around the world. Moreover, age, hormones, family * Yidong Fan [email protected] 1



Department of Urology, Shandong University Qilu Hospital, No. 107 Wenhua West Road, Jinan 250012, Shandong, China



The First Affiliated Hospital of University of Science and Technology of China, Hefei 230000, Anhui, China

2

history, genetic susceptibility and obesity are all risk factors responsible for the high morbidity of prostate cancer. Phosphatase and tensin homolog (PTEN) is a tumor suppressor gene with phosphatase activity, which is often inactivated